File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Robust SARS-CoV- 2 antibody and T cell immunity following three COVID-19 vaccine doses in inflammatory bowel disease patients receiving anti-TNF or alternative treatments

TitleRobust SARS-CoV- 2 antibody and T cell immunity following three COVID-19 vaccine doses in inflammatory bowel disease patients receiving anti-TNF or alternative treatments
Authors
Zhang, EvaNguyen, Thi H.O.Allen, Lilith F.Kedzierski, LukaszRowntree, Louise C.Chang, So YoungZhang, WujiHabel, Jennifer R.Foo, Isabelle J.Menon, TejasMitchell, JeniLeong, Rupert W.Bond, KatherineWilliamson, Deborah A.Kedzierska, KatherineChristensen, Britt
Issue Date2023
Citation
Gut, 2023, v. 73, n. 4, p. 712-714 How to Cite?
DOI: http://dx.doi.org/10.1136/gutjnl-2022-329136
Persistent Identifierhttp://hdl.handle.net/10722/355935
ISSN
0017-5749
2023 Impact Factor: 23.0
2023 SCImago Journal Rankings: 8.052
ISI Accession Number ID
WOS:000949956300001

 

DC FieldValueLanguage
dc.contributor.authorZhang, Eva-
dc.contributor.authorNguyen, Thi H.O.-
dc.contributor.authorAllen, Lilith F.-
dc.contributor.authorKedzierski, Lukasz-
dc.contributor.authorRowntree, Louise C.-
dc.contributor.authorChang, So Young-
dc.contributor.authorZhang, Wuji-
dc.contributor.authorHabel, Jennifer R.-
dc.contributor.authorFoo, Isabelle J.-
dc.contributor.authorMenon, Tejas-
dc.contributor.authorMitchell, Jeni-
dc.contributor.authorLeong, Rupert W.-
dc.contributor.authorBond, Katherine-
dc.contributor.authorWilliamson, Deborah A.-
dc.contributor.authorKedzierska, Katherine-
dc.contributor.authorChristensen, Britt-
dc.date.accessioned2025-05-19T05:46:46Z-
dc.date.available2025-05-19T05:46:46Z-
dc.date.issued2023-
dc.identifier.citationGut, 2023, v. 73, n. 4, p. 712-714-
dc.identifier.issn0017-5749-
dc.identifier.urihttp://hdl.handle.net/10722/355935-
dc.languageeng-
dc.relation.ispartofGut-
dc.titleRobust SARS-CoV- 2 antibody and T cell immunity following three COVID-19 vaccine doses in inflammatory bowel disease patients receiving anti-TNF or alternative treatments-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1136/gutjnl-2022-329136-
dc.identifier.pmid36878683-
dc.identifier.scopuseid_2-s2.0-85152201525-
dc.identifier.volume73-
dc.identifier.issue4-
dc.identifier.spage712-
dc.identifier.epage714-
dc.identifier.eissn1468-3288-
dc.identifier.isiWOS:000949956300001-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats